## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($49.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Marex Group plc Invests $948,000 in CRISPR Therapeutics AG $CRSP**
- Source: MarketBeat | 20251215T110857 | Neutral | Relevance: 100%
- Marex Group plc initiated a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during Q2, purchasing 19,483 shares valued at approximately $948,000. Institutional investors now own about 69.2% of the company, with several major firms increasing their stakes. Despite the company beating EPS estimates, its revenue missed, and insiders, including the CEO, have recently sold a significant number of shares.

**2. CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts**
- Source: MarketBeat | 20251213T070941 | Neutral | Relevance: 100%
- CRISPR Therapeutics AG (NASDAQ:CRSP) has received a consensus "Hold" rating from analysts, with an average one-year price target of $67.42. Despite some analysts issuing "buy" ratings and the company beating Q3 EPS estimates, significant insider selling has been noted, including CEO Samarth Kulkarni reducing his stake by 16.68%. Shares opened at $56.68, with a market cap of $5.4 billion, and the company reported Q3 revenue of $0.89 million, missing expectations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 6 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (26.4%, 8.9 days to cover): squeeze risk or crowded bearish bet.
3. Near-term weakness: 6.8% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.4B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 26.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 3.0% to 1.2% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 (-0.0%) diverging from MRS_10 - short-term weakness emerging. MACD histogram positive (0.72), confirming momentum. RSI neutral at 50. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.17% (CS: 37) | Neutral |
| RSI_14 | 49.6 | Neutral |
| MACD Histogram | 0.72 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 0.932x | Below |
| vs SMA200 | 1.106x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $56.25
- **Stop Loss:** $49.71 (11.6% risk)
- **Target:** $62.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 183
- **Position Value:** $10,293.75
- **Portfolio %:** 10.29%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*